Pankiewicz Piotr, Szybiński Marcin, Kisielewska Katarzyna, Gołębiowski Filip, Krzemiński Patryk, Rutkowska-Włodarczyk Izabela, Moszczyński-Pętkowski Rafał, Gurba-Bryśkiewicz Lidia, Delis Monika, Mulewski Krzysztof, Smuga Damian, Dominowski Jakub, Janusz Artur, Górka Michał, Abramski Krzysztof, Napiórkowska Agnieszka, Nowotny Marcin, Dubiel Krzysztof, Kalita Katarzyna, Wieczorek Maciej, Pieczykolan Jerzy, Matłoka Mikołaj
Celon Pharma Innovative Drugs Research & Development Department, Celon Pharma S.A., 05-152 Kazun Nowy, Poland.
Postgraduate School of Molecular Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Pharmaceuticals (Basel). 2021 Jul 21;14(8):704. doi: 10.3390/ph14080704.
TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF's action has been unsuccessful. Several molecules exerting antidepressive effects in vivo, such as 7,8-DHF, have been suggested to be TrkB agonists. However, more recent publications question this hypothesis. In this study, we developed a set of experimental procedures including the evaluation of direct interactions, dimerization, downstream signaling, and cytoprotection in parallel with physicochemical and ADME methods to verify the pharmacology of 7,8-DHF and other potential reference compounds, and perform screening for novel TrkB agonists. 7,8 DHF bound to TrkB with K = 1.3 μM; however, we were not able to observe any other activity against the TrkB receptor in SN56 T48 and differentiated SH-SY5Y cell lines. Moreover, the pharmacokinetic and pharmacodynamic effects of 7,8-DHF at doses of 1 and 50 mg/kg were examined in mice after i.v and oral administration, respectively. The poor pharmacokinetic properties and lack of observed activation of TrkB-dependent signaling in the brain confirmed that 7,8-DHF is not a relevant tool for studying TrkB activation in vivo. The binding profile for 133 molecular targets revealed a significant lack of selectivity of 7,8-DHF, suggesting a distinct functional profile independent of interaction with TrkB. Additionally, a compound library was screened in search of novel low-molecular-weight orthosteric TrkB agonists; however, we were not able to identify reliable drug candidates. Our results suggest that published reference compounds including 7,8-DHF do not activate TrkB, consistent with canonical dogma, which indicates that the reported pharmacological activity of these compounds should be interpreted carefully in a broad functional context.
TrkB是一种酪氨酸激酶受体,在与脑源性神经营养因子(BDNF)结合后被激活。迄今为止,寻找模拟BDNF作用的低分子量分子的研究尚未成功。几种在体内发挥抗抑郁作用的分子,如7,8-二氢黄酮(7,8-DHF),被认为是TrkB激动剂。然而,最近的一些出版物对这一假设提出了质疑。在本研究中,我们开发了一套实验程序,包括评估直接相互作用、二聚化、下游信号传导和细胞保护,并结合物理化学和药物代谢动力学方法,以验证7,8-DHF和其他潜在参考化合物的药理学特性,并筛选新型TrkB激动剂。7,8-DHF与TrkB的结合常数K = 1.3 μM;然而,在SN56 T48和分化的SH-SY5Y细胞系中,我们未能观察到其对TrkB受体的任何其他活性。此外,分别在静脉注射和口服给药后对小鼠进行了7,8-DHF剂量为1和50 mg/kg时的药代动力学和药效学效应研究。其较差的药代动力学特性以及在脑中未观察到TrkB依赖性信号传导的激活,证实了7,8-DHF并非用于研究体内TrkB激活的合适工具。对133个分子靶点的结合谱分析显示,7,8-DHF明显缺乏选择性,这表明其具有独立于与TrkB相互作用的独特功能谱。此外,我们还筛选了一个化合物库以寻找新型低分子量的正构TrkB激动剂;然而,我们未能鉴定出可靠的候选药物。我们的结果表明,包括7,8-DHF在内的已发表参考化合物不会激活TrkB,这与经典教条一致,即这些化合物所报道的药理活性应在更广泛的功能背景下谨慎解读。